Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02078648 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
A Phase 1 study, sponsored by Stemline Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02078648 is a Phase 1 study that has completed, run by Stemline Therapeutics. The registered enrollment target is 74 participants.
The verdict
NCT02078648, a Phase 1 study, has completed, sponsored by Stemline Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).
Interventions
- DRUG Bevacizumab
- DRUG Imiquimod
- DRUG SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
- DRUG SL-701 + GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02078648
The ClinicalTrials.gov registry entry for NCT02078648 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT02078648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02078648 about?
NCT02078648 is a clinical study titled "Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme". The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).
What is the current status of trial NCT02078648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2014-05. Estimated completion is 2018-01-22.
What interventions are being tested in trial NCT02078648?
The interventions under investigation include: Bevacizumab (DRUG), Imiquimod (DRUG), SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose) (DRUG), SL-701 + GM-CSF (DRUG).
Who is sponsoring clinical trial NCT02078648?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.